Keytruda

Merck touts new data for Keytruda combos in NSCLC at North American conference
Merck touts new data for Keytruda combos in NSCLC at North American conference
Endpoints
Merck
clinical trials
Keytruda
non-small cell lung cancer
IASLC
Flag link:
FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL
FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL
Pharmaceutical Business Review
Merck
FDA
Keytruda
Hodgkin's lymphoma
Flag link:
Sensei raises $29M to advance anti-cancer bacteriophage pipeline
Sensei raises $29M to advance anti-cancer bacteriophage pipeline
Fierce Biotech
Sensei Biotherapeutics
SNS-301
Merck
Keytruda
bacteriophage
Flag link:
ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study
ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study
BioSpace
ALX Oncology
Merck
head and neck cancer
ALX148
Keytruda
Flag link:
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
Fierce Pharma
ESMO
Roche
Tecentriq
triple negative breast cancer
Merck
Keytruda
Flag link:
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
ovarian cancer
colorectal cancer
Flag link:
ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer
ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer
Fierce Pharma
Merck
ESMO
bladder cancer
metastatic bladder cancer
Keytruda
Flag link:
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
Fierce Biotech
Alkermes
immuno-oncology
ESMO
ALKS 4230
Keytruda
Flag link:
Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails
Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails
Pharmaforum
Highlight Therapeutics
melanoma
BO-112
Keytruda
Merck
Flag link:
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
Fierce Pharma
Eli Lilly
Innovent Biologics
China
non-small cell lung cancer
Tyvyt
Merck
Keytruda
Flag link:
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
BioSpace
Merck
Novocure
clinical trials
tumor treating fields
Keytruda
non-small cell lung cancer
Flag link:
FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch
FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch
Endpoints
Merck
FDA
complete response letter
Keytruda
Eisaid
Lenvima
hepatocellular carcinoma
Roche
Flag link:
Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review
Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review
Pharmaforum
Merck
Keytruda
FDA
colorectal cancer
Flag link:
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
Flag link:
Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK
Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK
Fierce Pharma
Merck
Keytruda
FDA
squamous cell carcinoma
Sanofi
Regeneron
Libtayo
Flag link:
Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Endpoints
Merck
Keytruda
Bristol-Myers Squibb
FDA
biomarkers
accelerated approvals
cancer
TMB
Flag link:
Merck & Co’s Keytruda fails in first line bladder cancer
Merck & Co’s Keytruda fails in first line bladder cancer
Pharmaforum
Merck
Keytruda
bladder cancer
Flag link:
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
Pharmaforum
ASCO 2020
Amgen
AstraZeneca
Bristol-Myers Squibb
cancer
CAR-T
COVID-19
Keytruda
Kyprolis
Tagrisso
Flag link:
ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients
ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients
Fierce Pharma
Merck
Keytruda
clinical trials
ASCO 2020
colorectal cancer
Flag link:
ASCO 2020 – first-line lung cancer focus
ASCO 2020 – first-line lung cancer focus
EP Vantage
Roche
Merck
Bristol-Myers Squibb
ASCO 2020
lung cancer
Keytruda
tiragolumab
Opdivo
Yervoy
Flag link:

Pages